Medacta reported 1H23 orthopedic sales of €255.2 million ($275.6 million USD), +20.8% compared to the first half of 2022.
The company kept its organic growth momentum after growing more than 20% in both 2021 and 2022. In addition to continued strong performances in the EMEA region, Medacta saw recoveries in the APAC and U.S. markets as disruption-related backlogs are worked down. Unlike some of its competitors, the company reported a robust supply chain able to support accelerating growth.
Medacta’s joint replacement sales were especially strong in the first half of 2023, even when accounting for a somewhat inflated market. The company’s hip sales benefited from the Anterior Minimally Invasive Surgery Approach (AMIS), while its personalized knee solutions drove growth across all regions. Medacta’s MyShoulder and NextAR systems drove growth in its extremities category.
For 2023, the company expects sales growth in the range of 15% to 18%, implying total revenues between $542.9 million and $557 million.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. We estimate orthopedic sales and growth on an as-reported basis.
Orthopedic Sales by Segment
1H22
1H21
$ Chg
% Chg
Joint Replacement
$247.5
$203.6
$43.9
21.6%
Knees
$106.4
$83.4
$22.9
27.5%
Hips
$123.2
$107.3
$15.9
14.8%
Extremities
$17.9
$12.9
$5.0
39.1%
Spine
$23.6
$20.8
$2.8
13.4%
Sports Medicine
$0.9
$0.6
$0.2
39.1%
Enabling Technology
$3.7
$3.1
$0.6
17.8%
Total
$275.6
$228.2
$47.5
20.8%
Orthopedic Sales by Geography
1H22
1H21
$ Chg
% Chg
US
$82.6
$69.3
$13.3
19.2%
OUS
$193.0
$158.8
$34.2
21.5%
EMEA
$132.9
$101.9
$31.1
30.5%
APAC
$55.5
$48.4
$7.1
14.7%
ROW
$4.5
$8.5
($4.0)
(46.9%)
Total
$275.6
$228.2
$47.5
20.8%
Medacta reported 1H23 orthopedic sales of €255.2 million ($275.6 million USD), +20.8% compared to the first half of 2022.
The company kept its organic growth momentum after growing more than 20% in both 2021 and 2022. In addition to continued strong performances in the EMEA region, Medacta saw recoveries in the APAC and U.S. markets as...
Medacta reported 1H23 orthopedic sales of €255.2 million ($275.6 million USD), +20.8% compared to the first half of 2022.
The company kept its organic growth momentum after growing more than 20% in both 2021 and 2022. In addition to continued strong performances in the EMEA region, Medacta saw recoveries in the APAC and U.S. markets as disruption-related backlogs are worked down. Unlike some of its competitors, the company reported a robust supply chain able to support accelerating growth.
Medacta’s joint replacement sales were especially strong in the first half of 2023, even when accounting for a somewhat inflated market. The company’s hip sales benefited from the Anterior Minimally Invasive Surgery Approach (AMIS), while its personalized knee solutions drove growth across all regions. Medacta’s MyShoulder and NextAR systems drove growth in its extremities category.
For 2023, the company expects sales growth in the range of 15% to 18%, implying total revenues between $542.9 million and $557 million.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. We estimate orthopedic sales and growth on an as-reported basis.
Orthopedic Sales by Segment
1H22
1H21
$ Chg
% Chg
Joint Replacement
$247.5
$203.6
$43.9
21.6%
Knees
$106.4
$83.4
$22.9
27.5%
Hips
$123.2
$107.3
$15.9
14.8%
Extremities
$17.9
$12.9
$5.0
39.1%
Spine
$23.6
$20.8
$2.8
13.4%
Sports Medicine
$0.9
$0.6
$0.2
39.1%
Enabling Technology
$3.7
$3.1
$0.6
17.8%
Total
$275.6
$228.2
$47.5
20.8%
Orthopedic Sales by Geography
1H22
1H21
$ Chg
% Chg
US
$82.6
$69.3
$13.3
19.2%
OUS
$193.0
$158.8
$34.2
21.5%
EMEA
$132.9
$101.9
$31.1
30.5%
APAC
$55.5
$48.4
$7.1
14.7%
ROW
$4.5
$8.5
($4.0)
(46.9%)
Total
$275.6
$228.2
$47.5
20.8%
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
